A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.
| Status: | Completed |
|---|---|
| Conditions: | High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/22/2017 |
| Start Date: | October 2005 |
| End Date: | June 2006 |
A Multicenter, Double-blind, Randomized, Active Controlled, Parallel Group Trial Comparing the Combinations of Valsartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Valsartan 80 mg in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 80mg
Valsartan, an orally active angiotensin II receptor blocker, is registered in most countries
worldwide for the treatment of hypertension. In China the usual recommended starting and
maintenance dose is 80 mg o.d. The combination of HCTZ 12.5 mg with valsartan 80 mg has been
shown to have additive effects in lowering blood pressure compared to valsartan 80 mg in
patients not adequately controlled by valsartan 80 mg monotherapy5 or in non-selected
patients6. This fixed combination is registered in most countries worldwide.
The potential benefits of these combinations should be evaluated in patients not adequately
controlled by valsartan 80 mg monotherapy. This study will compare the efficacy, safety and
tolerability of adding HCTZ 12.5 mg to valsartan 80 mg in those hypertensive patients.
This study is not recruiting in the US.
worldwide for the treatment of hypertension. In China the usual recommended starting and
maintenance dose is 80 mg o.d. The combination of HCTZ 12.5 mg with valsartan 80 mg has been
shown to have additive effects in lowering blood pressure compared to valsartan 80 mg in
patients not adequately controlled by valsartan 80 mg monotherapy5 or in non-selected
patients6. This fixed combination is registered in most countries worldwide.
The potential benefits of these combinations should be evaluated in patients not adequately
controlled by valsartan 80 mg monotherapy. This study will compare the efficacy, safety and
tolerability of adding HCTZ 12.5 mg to valsartan 80 mg in those hypertensive patients.
This study is not recruiting in the US.
Inclusion Criteria:
- - Male or female Outpatients 18 years and older.
- Patients with hypertension defined as the following:
- Newly diagnosed hypertensive patients should have a MSDBP > 95 mmHg and < 110 mmHg.at
Visit 1 and 2, Pre-treated hypertensive patients should have a MSDBP > 95 mmHg and <
110 mmHg at Visit 2
- For entrance into the double-blind treatment period (Visit 3), all patients should
have a MSDBP of > 90 mmHg and < 110 mmHg
- Patients must have given written informed consent to participate and be willing to
participate in the entire study
Exclusion Criteria:
We found this trial at
1
site
Click here to add this to my saved trials
